株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のバイオシミラー市場の分析と予測:製品、応用分野(腫瘍、成長ホルモン、血液疾患、慢性疾患、自己免疫疾患)、地域別 2018年〜2025年

Biosimilars Market Size, Share & Trends Analysis Report By Product, By Application (Oncology, Growth Hormone, Blood Disorders, Chronic & Autoimmune Disorders), By Region, And Segment Forecasts, 2018 - 2025

発行 Grand View Research, Inc. 商品コード 544803
出版日 ページ情報 英文 70 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
世界のバイオシミラー市場の分析と予測:製品、応用分野(腫瘍、成長ホルモン、血液疾患、慢性疾患、自己免疫疾患)、地域別 2018年〜2025年 Biosimilars Market Size, Share & Trends Analysis Report By Product, By Application (Oncology, Growth Hormone, Blood Disorders, Chronic & Autoimmune Disorders), By Region, And Segment Forecasts, 2018 - 2025
出版日: 2018年07月17日 ページ情報: 英文 70 Pages
概要

世界のバイオシミラー市場は、2018年から2025年にかけて34.2%のCAGRで推移し、2025年までに614億7,000万米ドル規模の市場に成長することが予測されています。多くの主要バイオ医薬品の特許期間の満了が迫っており、多くの企業がバイオシミラーの開発に取り組んでいます。

当レポートでは、世界のバイオシミラー市場を調査し、市場の概要、製品・応用分野・地域別の市場規模の推移と予測、市場動向、市場シェア、成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法

第2章 エグゼクティブサマリー

  • 市場概要

第3章 市場変数・動向・範囲

  • 市場区分と範囲
  • 成長要因と分析
  • 阻害要因と分析
  • 市場機会
  • SWOT分析
  • ファイブフォース分析
  • 競合情勢:市場ポジショニング分析

第4章 世界のバイオシミラー市場の分析と予測:製品別

  • 市場動向の分析:製品別
  • 組換え非グルコシル化タンパク質
    • ヒト成長ホルモン
    • 顆粒球コロニー刺激因子
    • インターフェロン
    • インスリン
  • 組換えグリコシル化タンパク質
    • エリスロポエチン
    • モノクローナル抗体
    • フォリトロピン

第5章 世界のバイオミシラー市場の分析と予測:応用分野別

  • 市場動向の分析:応用分野別
  • 腫瘍
  • 血液疾患
  • 成長ホルモン欠乏症
  • 慢性疾患・自己免疫疾患
  • その他

第6章 世界のバイオシミラー市場の分析と予測:地域別

  • 市場シェア:地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域

第7章 競合情勢

  • 企業プロファイル
    • Amgen Inc.
    • F Hoffmann-La Roche Ltd
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Samsung Bioepis
    • Biocon
    • Mylan N.V.
    • Celltrion Healthcare
    • AbbVie Inc
図表

List of Tables

  • TABLE 1 Factors used in segment share estimation
  • TABLE 2 List of secondary data sources
  • TABLE 3 Primary interview details, by source
  • TABLE 4 Primary interview details, by region
  • TABLE 5 North America biosimilars market, by country, 2014 - 2025 (USD Million)
  • TABLE 6 North America biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 7 North America biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 8 North America biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 9 North America biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 10 U.S. biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 11 U.S. biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 12 U.S. biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 13 U.S. biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 14 Canada biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 15 Canada biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 16 Canada biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 17 Canada biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 18 Europe biosimilars market, by country, 2014 - 2025 (USD Million)
  • TABLE 19 Europe biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 20 Europe biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 21 Europe biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 22 Europe biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 23 Germany biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 24 Germany biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 25 Germany biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 26 Germany biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 27 U.K. biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 28 U.K. biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 29 U.K. biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 30 U.K. biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 31 Asia Pacific biosimilars market, by country, 2014 - 2025 (USD Million)
  • TABLE 32 Asia Pacific biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 33 Asia Pacific biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 34 Asia Pacific biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 35 Asia Pacific biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 36 China biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 37 China biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 38 China biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 39 China biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 40 India biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 41 India biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 42 India biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 43 India biosimilars market, by application, 2014 - 2025 (USD Million)
  • TABLE 44 ROW biosimilars market, by product, 2014 - 2025 (USD Million)
  • TABLE 45 ROW biosimilars market, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 46 ROW biosimilars market, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
  • TABLE 47 ROW biosimilars market, by application, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Primary interviews, by sources
  • FIG. 2 Primary interviews, by region
  • FIG. 3 Market summary
  • FIG. 4 Market trends & outlook
  • FIG. 5 Market segmentation & scope
  • FIG. 6 Market driver relevance analysis (Current & future impact)
  • FIG. 7 Key opportunities prioritized, by product
  • FIG. 8 Key opportunities prioritized, by application
  • FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • FIG. 10 Porter's five forces analysis
  • FIG. 11 Market position analysis, 2016
  • FIG. 12 Biosimilars market product outlook: Key takeaways
  • FIG. 13 Biosimilars market: Product movement analysis
  • FIG. 14 Recombinant non-glycosylated proteins market, 2014 - 2025 (USD Million)
  • FIG. 15 Human growth hormone market, 2014 - 2025 (USD Million)
  • FIG. 16 Granulocyte colony-stimulating factor market, 2014 - 2025 (USD Million)
  • FIG. 17 Interferons market, 2014 - 2025 (USD Million)
  • FIG. 18 Insulin market, 2014 - 2025 (USD Million)
  • FIG. 19 Recombinant glycosylated proteins market, 2014 - 2025 (USD Million)
  • FIG. 20 Erythropoietin market, 2014 - 2025 (USD Million)
  • FIG. 21 Monoclonal antibodies market, 2014 - 2025 (USD Million)
  • FIG. 22 Follitropin market, 2014 - 2025 (USD Million)
  • FIG. 23 Biosimilars market application outlook: Key takeaways
  • FIG. 24 Biosimilars market: Application movement analysis
  • FIG. 25 Oncology market, 2014 - 2025 (USD Million)
  • FIG. 26 Blood disorders market, 2014 - 2025 (USD Million)
  • FIG. 27 Growth hormonal deficiency market, 2014 - 2025 (USD Million)
  • FIG. 28 Chronic and autoimmune disorders market, 2014 - 2025 (USD Million)
  • FIG. 29 Others market, 2014 - 2025 (USD Million)
  • FIG. 30 Regional market place: Key takeaways
  • FIG. 31 Regional outlook, 2016 & 2025
目次
Product Code: 978-1-68038-916-6

The global biosimilars market size is expected to reach a value of USD 61.47 billion by 2025, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 34.2% over the forecast period. Major biological drugs are approaching the patent cliff. This is the most significant driving factor for the market. For instance, Roche's MabThera/Rituxan (rituximab), a monoclonal antibody biologics was approved by the U.S. Food and Drug Administration (FDA) in November 1997 and its U.S. patent expired in September 2016. Several companies such as Amgen, Boehringer Ingelheim, and Pfizer are focusing on development of biosimilar drug of rituximab.

Furthermore, lower cost of biosimilars compared to patented biologics and positive outcomes in clinical trials are expected to boost market growth. For instance, in July 2016; Allergan plc and Amgen stated results from a Phase 3 clinical study of ABP 980 compared with trastuzumab, a recombinant DNA-derived humanized monoclonal antibody. This drug was approved for early and metastatic breast cancer and metastatic gastric cancer in many regions. Currently, there is a boom in pharmaceutical industry for the development of biosimilar drugs, which is a cost-saving alternative to biologic drugs. Amgen Inc.; Sandoz International GmbH; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Biocon; Samsung Bioepis; and Mylan N.V are some of the companies focusing on the development and production of biosimilars.

Further key findings from the report suggest:

  • In 2016, recombinant non-glycosylated protein was the largest revenue-grossing segment in the biosimilars market owing to prevalence of growth hormone deficiency and diabetes and other chronic diseases
  • Recombinant glycosylated protein segment is expected to grow at significant rate during the forecast period owing to demand for erythropoietin and monoclonal antibodies for treatment of cancer and anemia
  • Oncology accounted for the largest share in application segment in 2016 due to increasing adoption of low cost biosimilar drugs for cancer treatment
  • Europe was the leading regional segment in terms of revenue share in 2016 owing to favorable regulatory policies
  • North America is expected to witness the highest CAGR during the forecast period owing to high prevalence of chronic diseases and rising number of drug approvals

Some of the major players are: Amgen Inc.; F. Hoffmann-La Roche Ltd.; Sandoz International GmbH; Dr. Reddy's Laboratories Ltd.; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Samsung Bioepis; Biocon; and Mylan N.V.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Country Wise Market: Base Estimates
  • 1.2 Global Market: CAGR Calculation
  • 1.3 Region Based Segment Share Calculation
  • 1.4 Research Scope & Assumptions
  • 1.5 List of Data Sources
    • 1.5.1 Data for primary interviews, by sources
    • 1.5.2 Data for primary interviews, by region

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Biosimilars Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Increasing emphasis on cutting down healthcare expenditures
    • 3.2.2 Cost effectiveness of biosimilar drugs
    • 3.2.3 Positive outcome in the ongoing clinical trials
    • 3.2.4 R&D investments are increasing
    • 3.2.5 Patent expiration of biologics to boost the biosimilars market
  • 3.3 Market Restraint Analysis
    • 3.3.1 High manufacturing complexities and costs
    • 3.3.2 Presence of non-original biologics and biobetters
  • 3.4 Key Opportunities Prioritized
    • 3.4.1 Key opportunities prioritized, by product
    • 3.4.2 Key opportunities prioritized, by application
  • 3.5 Biosimilars- SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.6 Industry Analysis - Porter's
  • 3.7 Competitive Landscape: Market Position Analysis, 2016

Chapter 4 Biosimilars Market: Product Estimates & Trend Analysis

  • 4.1 Biosimilars Market: Product Movement Analysis
  • 4.2 Recombinant Non-Glycosylated Proteins
    • 4.2.1 Recombinant non-glycosylated proteins market, 2014 - 2025 (USD Million)
    • 4.2.2 Human growth hormone
      • 4.2.2.1 Human growth hormone market, 2014 - 2025 (USD Million)
    • 4.2.3 Granulocyte colony-stimulating factor
      • 4.2.3.1 Granulocyte colony-stimulating factor market, 2014 - 2025 (USD Million)
    • 4.2.4 Interferons
      • 4.2.4.1 Interferons market, 2014 - 2025 (USD Million)
    • 4.2.5 Insulin
      • 4.2.5.1 Insulin market, 2014 - 2025 (USD Million)
  • 4.3 Recombinant Glycosylated Proteins
    • 4.3.1 Recombinant glycosylated proteins market, 2014 - 2025 (USD Million)
    • 4.3.2 Erythropoietin
      • 4.3.2.1 Erythropoietin market, 2014 - 2025 (USD Million)
    • 4.3.3 Monoclonal antibodies
      • 4.3.3.1 Monoclonal antibodies market, 2014 - 2025 (USD Million)
    • 4.3.4 Follitropin
      • 4.3.4.1 Follitropin market, 2014 - 2025 (USD Million)

Chapter 5 Biosimilars Market: Application Estimates & Trend Analysis

  • 5.1 Biosimilars Market: Application Movement Analysis
  • 5.2 Oncology
    • 5.2.1 Oncology market, 2014 - 2025 (USD Million)
  • 5.3 Blood Disorders
    • 5.3.1 Blood disorders market, 2014 - 2025 (USD Million)
  • 5.4 Growth Hormonal Deficiency
    • 5.4.1 Growth hormonal deficiency market, 2014 - 2025 (USD Million)
  • 5.5 Chronic and Autoimmune Disorders
    • 5.5.1 Chronic and autoimmune disorders market, 2014 - 2025 (USD Million)
  • 5.6 Others
    • 5.6.1 Others market, 2014 - 2025 (USD Million)

Chapter 6 Biosimilars Market: Regional Estimates & Trend Analysis, by Product and Application

  • 6.1 Biosimilars Market Share by Region, 2016 & 2025
  • 6.2 North America
    • 6.2.1 U.S.
      • 6.2.1.1 U.S. biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.2.1.2 U.S. biosimilars market, by application, 2014 - 2025 (USD Million)
    • 6.2.2 Canada
      • 6.2.2.1 Canada biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.2.2.2 Canada biosimilars market, by application, 2014 - 2025 (USD Million)
  • 6.3 Europe
    • 6.3.1 Germany
      • 6.3.1.1 Germany biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.3.1.2 Germany biosimilars market, by application, 2014 - 2025 (USD Million)
    • 6.3.2 U.K.
      • 6.3.2.1 U.K. biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.3.2.2 U.K. biosimilars market, by application, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 China
      • 6.4.1.1 China biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.4.1.2 China biosimilars market, by application, 2014 - 2025 (USD Million)
    • 6.4.2 India
      • 6.4.2.1 India biosimilars market, by product, 2014 - 2025 (USD Million)
      • 6.4.2.2 India biosimilars market, by application, 2014 - 2025 (USD Million)
  • 6.5 ROW

Chapter 7 Competitive Landscape

  • 7.1 Company Profiles
    • 7.1.1 Amgen Inc.
      • 7.1.1.1 Company overview
      • 7.1.1.2 Financial performance
      • 7.1.1.3 Product benchmarking
      • 7.1.1.4 Strategic initiatives
    • 7.1.2 F Hoffmann-La Roche Ltd
      • 7.1.2.1 Company overview
      • 7.1.2.2 Financial performance
      • 7.1.2.3 Product benchmarking
      • 7.1.2.4 Strategic initiatives
    • 7.1.3 Sandoz International GmbH
      • 7.1.3.1 Company overview
      • 7.1.3.2 Financial performance
      • 7.1.3.3 Product benchmarking
      • 7.1.3.4 Strategic initiatives
    • 7.1.4 Dr. Reddy's Laboratories Ltd.
      • 7.1.4.1 Company overview
      • 7.1.4.2 Financial performance
      • 7.1.4.3 Product benchmarking
      • 7.1.4.4 Strategic initiatives
    • 7.1.5 Teva Pharmaceutical Industries Ltd.
      • 7.1.5.1 Company overview
      • 7.1.5.2 Financial performance
      • 7.1.5.3 Product benchmarking
      • 7.1.5.4 Strategic initiatives
    • 7.1.6 Pfizer Inc.
      • 7.1.6.1 Company overview
      • 7.1.6.2 Financial performance
      • 7.1.6.3 Product benchmarking
      • 7.1.6.4 Strategic initiatives
    • 7.1.7 Samsung Bioepis
      • 7.1.7.1 Company overview
      • 7.1.7.2 Financial performance
      • 7.1.7.3 Product benchmarking
      • 7.1.7.4 Strategic initiatives
    • 7.1.8 Biocon
      • 7.1.8.1 Company overview
      • 7.1.8.2 Financial performance
      • 7.1.8.3 Product benchmarking
      • 7.1.8.4 Strategic initiatives
    • 7.1.9 Mylan N.V.
      • 7.1.9.1 Company overview
      • 7.1.9.2 Financial performance
      • 7.1.9.3 Product benchmarking
      • 7.1.9.4 Strategic initiatives
    • 7.1.10 Celltrion Healthcare
      • 7.1.10.1 Company overview
      • 7.1.10.2 Financial performance
      • 7.1.10.3 Product benchmarking
      • 7.1.10.4 Strategic initiatives
    • 7.1.11 AbbVie Inc.
      • 7.1.11.1 Company overview
      • 7.1.11.2 Financial performance
      • 7.1.11.3 Product benchmarking
      • 7.1.11.4 Strategic initiatives
Back to Top